| SESN - Sesen Bio Inc (Healthcare: Biotechnology) | Projected Earnings Date: 2023-08-11 (Delayed quote data ) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Sesen Bio Inc is a late-stage clinical company engaged in next-generation antibody-drug conjugate therapies for the treatment of cancer-based on the company's Targeted Protein Therapeutics platform. The company's lead program, Vicinium, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive NMIBC. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |